Zimmer Biomet reported first quarter earnings at $299 million, nearly tripling earnings from the first quarter last year, despite production slowing.
But CEO David Dvorak is not deterred and remains optimistic about the company’s future. In the quarterly financial report conference call, Mr. Dvorak said the company’s recent struggles with an internal and FDA audits that found issues to address weren’t associated with competition.
In a transcript from Seeking Alpha, Mr. Dvorak described the process as “two steps forward and one step back” and said, “We’ve made accelerated changes to those operations…it just took us longer to ramp up that production in the first quarter than we originally anticipated.”
Mr. Dvorak reported production levels should increase in the coming months and hospitals will have access to their usual implant volume by the end of June. He is positioning the company for acceleration in the second half of the year and expects to launch around 40 new products this year, according to the report.
More articles on orthopedic devices:
5 key notes on NuVasive’s Q1: total revenue up 16.2% to $249.9M
Exactech Q1 2017revenue hits $69.5M
Nexxt Spine releases Intertial Corti-Fixx pedicle screw system: 4 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
